SCHEMBL13060461

SCHEMBL13060461

CC(C)(CCCCc1c[nH]c2ncnc(Cl)c12)[Si](C)(C)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.40
▸ NOTUM Q6P988 1/20 0.31
▸ AKT1 P31749 1/20 0.30
▸ PLK4 O00444 1/20 0.30
▸ AURKA O14965 1/20 0.30
▸ DCLK1 O15075 1/20 0.30
▸ ROCK2 O75116 1/20 0.30
▸ PRKD3 O94806 1/20 0.30
▸ MAP4K4 O95819 1/20 0.30
▸ CDK1 P06493 1/20 0.30
▸ FES P07332 1/20 0.30
▸ ROS1 P08922 1/20 0.30
▸ FGFR1 P11362 1/20 0.30
▸ PHKG2 P15735 1/20 0.30
▸ PRKACA P17612 1/20 0.30
▸ FLT1 P17948 1/20 0.30
▸ RPS6KB1 P23443 1/20 0.30
▸ CDK2 P24941 1/20 0.30
▸ MARK3 P27448 1/20 0.30
▸ FLT4 P35916 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13060746 0.96 CHEK1 (0.41) CHEK1NOTUMAKT1PLK4AURKA
SCHEMBL13005543 0.76 CHEK1 (0.40) CHEK1PLK4AURKAROCK2PRKD3
SCHEMBL31618054 0.76 CHEK1 (0.40) CHEK1PLK4AURKAROCK2PRKD3
SCHEMBL2783376 0.74 CHEK1 (0.53) CHEK1NOTUMAKT1PLK4AURKA
SCHEMBL16765141 0.73 CHEK1 (0.49) CHEK1NOTUMAKT1PLK4AURKA
SCHEMBL3285768 0.72 CHEK1 (0.42) CHEK1AKT1PLK4AURKAROCK2
SCHEMBL3236479 0.71 CHEK1 (0.56) CHEK1NOTUMPLK4AURKADCLK1
SCHEMBL4780230 0.71 CHEK1 (0.56) CHEK1NOTUMAKT1AURKAIRAK4
SCHEMBL16765811 0.71 CHEK1 (0.49) CHEK1NOTUMPLK4AURKAROCK2
SCHEMBL3224749 0.69 CHEK1 (0.44) CHEK1NOTUMAKT1AURKAPRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311684-A1 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2010-12-09 — — US disclosed
US-7268119-B2 Tricyclic nucleosides or nucleotides as therapeutic agents BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2007-09-11 — — US disclosed
US-20070135363-A1 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS BIOTA, INC. (US) 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135363-A1 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS NTPCR, NME1, NME2 CHEK1 484/4885NOTUM 4768/4885AKT1 804/4885
US-20100311684-A1 NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS NTPCR, NME1, NME2 CHEK1 484/4885NOTUM 4768/4885AKT1 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback